116 related articles for article (PubMed ID: 10774572)
1. Endocrinological study of the dopaminergic regulation of prolactin release in metastatic breast cancer.
Mandalà M; Lissoni P; Ardizzoia A; Barni S; Rovelli F; Confalonieri G; Malugani F; Moro C; Fumagalli G; Giani L; Tancini G
Tumori; 1999; 85(6):494-7. PubMed ID: 10774572
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia.
Lissoni P; Mandalà M; Rovelli F; Casu M; Rocco F; Tancini G; Scardino E
Eur Urol; 2000 May; 37(5):569-72. PubMed ID: 10765095
[TBL] [Abstract][Full Text] [Related]
3. Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.
Lissoni P; Malugani F; Casu M; Bukovec R; Egardi R; Bordin V; Fumagalli E; Mengo S; Gardani G
Neuro Endocrinol Lett; 2002 Feb; 23(1):61-3. PubMed ID: 11880864
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Lissoni P; Vaghi M; Ardizzoia A; Fumagalli E; Tancini G; Gardani G; Conti A; Maestroni GJ
Neuro Endocrinol Lett; 2001; 22(1):27-9. PubMed ID: 11335876
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin.
Méndez I; Alcocer-Varela J; Parra A; Lava-Zavala A; de la Cruz DA; Alarcón-Segovia D; Larrea F
Lupus; 2004; 13(1):45-53. PubMed ID: 14870917
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery.
Barbarino A; De Marinis L; Anile C; Menini E; Merlini G; Maira G
Metabolism; 1982 Nov; 31(11):1100-4. PubMed ID: 6813636
[TBL] [Abstract][Full Text] [Related]
7. The interrelationships between prolactin and thyrotrophin secretion following dopaminergic blockage in patients with mild hyperprolactinaemia without any demonstrable pituitary tumour.
Spitz IM; Haas M; Trestian S; Zylber-Haran E; Shilo S
Clin Endocrinol (Oxf); 1983 Sep; 19(3):285-94. PubMed ID: 6414745
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer.
Barni S; Lissoni P; Meregalli S; Ardizzoia A; Mengo S; Musco F; Merlini D; Tancini G
Tumori; 1998; 84(1):45-7. PubMed ID: 9619713
[TBL] [Abstract][Full Text] [Related]
9. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
Fine SA; Frohman LA
J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
[TBL] [Abstract][Full Text] [Related]
10. Prolactin and growth hormone secretion after thyrotrophin-releasing hormone infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild endometriosis.
Cunha-Filho JS; Gross JL; Lemos NA; Dias EC; Vettori D; Souza CA; Passos EP
Hum Reprod; 2002 Apr; 17(4):960-5. PubMed ID: 11925390
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer.
Frontini L; Lissoni P; Vaghi M; Perego MS; Pescia S; Ardizzoia A; Gardani G
Anticancer Res; 2004; 24(6):4223-6. PubMed ID: 15736476
[TBL] [Abstract][Full Text] [Related]
12. HER2 expression in breast cancer: correlation with endocrine function and psychological status in operable and metastatic breast cancer.
Lissoni P; Messina G; Rovelli F; Brivio F; Fumagalli L; Villa S; Bartolacelli E
In Vivo; 2009; 23(6):987-9. PubMed ID: 20023245
[TBL] [Abstract][Full Text] [Related]
13. A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines.
Lissoni P; Bucovec R; Malugani F; Ardizzoia A; Villa S; Gardani GS; Vaghi M; Tancini G
Anticancer Res; 2002; 22(2B):1131-4. PubMed ID: 12168912
[TBL] [Abstract][Full Text] [Related]
14. Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia.
Lissoni P; Vaghi M; Pescia S; Rovelli F; Ardizzola A; Valtulina F; Malugani F; Gardani G; Tancini G
J Biol Regul Homeost Agents; 2004; 18(3-4):291-4. PubMed ID: 15786695
[TBL] [Abstract][Full Text] [Related]
15. Prolactin response to metoclopramide and thyrotropin-releasing hormone in normoprolactinemic and hyperprolactinemic women: a comparison of diagnostic validity.
Bussen S; Brosemann N; Steck T
Gynecol Endocrinol; 1996 Apr; 10(2):83-90. PubMed ID: 8701791
[TBL] [Abstract][Full Text] [Related]
16. Increased hypothalamic dopaminergic tone only in early parous women with either malignant or benign breast tumors.
Ortega-González C; Parra A; Barra R; Aranda C; Ramírez D; Di Castro P; Castro I; Zambrana M; Coria I
Endocr Pract; 2002; 8(2):89-95. PubMed ID: 11942771
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin.
Barni S; Lissoni P; Brivio F; Fumagalli L; Merlini D; Cataldo M; Rovelli F; Tancini G
Tumori; 1994 Jun; 80(3):212-5. PubMed ID: 8053079
[TBL] [Abstract][Full Text] [Related]
18. Effect of ghrelin and metoclopramide on prolactin secretion in normal women.
Messini CI; Dafopoulos K; Chalvatzas N; Georgoulias P; Anifandis G; Messinis IE
J Endocrinol Invest; 2011 Apr; 34(4):276-9. PubMed ID: 20530986
[TBL] [Abstract][Full Text] [Related]
19. Prolactin regulation of tuberoinfundibular dopaminergic neurons: immunoneutralization studies.
Hentschel K; Fleckenstein AE; Toney TW; Lawson DM; Moore KE; Lookingland KJ
Brain Res; 2000 Jan; 852(1):28-36. PubMed ID: 10661492
[TBL] [Abstract][Full Text] [Related]
20. Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome.
Hernández I; Parra A; Méndez I; Cabrera V; Cravioto MC; Mercado M; Díaz-Sánchez V; Larrea F
Arch Med Res; 2000; 31(2):216-22. PubMed ID: 10880731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
